A mutation-independent therapeutic strategy for dominant dystrophic epidermolysis bullosa

J Invest Dermatol. 2013 Dec;133(12):2793-2796. doi: 10.1038/jid.2013.241. Epub 2013 Jun 6.

Authors

Clare P Morgan¹, Danny S I Allen², Sophia Millington-Ward², Gareth E O'Dwyer², Arpad Palfi², G Jane Farrar²

Affiliations

¹ Department of Genetics, Trinity College Dublin, Dublin, Ireland. Electronic address: clmorgan@tcd.ie.
² Department of Genetics, Trinity College Dublin, Dublin, Ireland.

PMID: 23743647
DOI: 10.1038/jid.2013.241

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cell Line
Collagen Type VII / genetics*
Epidermolysis Bullosa Dystrophica / genetics*
Epidermolysis Bullosa Dystrophica / therapy
Fibroblasts / cytology
Gene Silencing*
Genetic Therapy / methods
HEK293 Cells
Humans
Keratinocytes / metabolism
Mutation*
RNA Interference

Substances

COL7A1 protein, human
Collagen Type VII